PT-141 (Bremelanotide) 10 mg

PT-141 (Bremelanotide) 10 mg is Hilma Biocare's melanocortin peptide, supplied as a single lyophilised vial. It is studied for central libido rather than blood flow, which distinguishes it from PDE5 inhibitors.

What PT-141 Is

Bremelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone that acts on melanocortin receptors in the central nervous system. Its primary research interest is sexual desire and arousal, which it influences through MC4R signalling in the hypothalamus. Because it works centrally rather than on vascular smooth muscle, it is pharmacologically distinct from sildenafil and tadalafil. The 10 mg vial is the standard presentation.

The History of PT-141

Bremelanotide was developed by Palatin Technologies in the 1990s and 2000s, derived from the same melanocortin research that produced Melanotan II. Early studies noted effects on sexual arousal, and the compound was developed specifically for hypoactive sexual desire disorder. It was approved in 2019 as Vyleesi, becoming the first centrally acting treatment for low sexual desire in premenopausal women.

How It Works

PT-141 binds melanocortin receptors, particularly MC4R, in the hypothalamus and limbic system. That activation influences dopaminergic pathways involved in desire and arousal. Unlike PDE5 inhibitors, it does not require nitric oxide signalling or vascular relaxation to produce its effect. The peptide is metabolised rapidly, and its central action means the effect is on motivation rather than blood flow.

What the Research Shows

• Clinical trials examined bremelanotide for hypoactive sexual desire disorder.
• Studies show improved desire and reduced distress in participants.
• Its central melanocortin mechanism is well characterised.
• Nausea and blood-pressure effects are documented in trials.

Research Context

Bremelanotide's development path is unusual because it targeted desire rather than mechanics. Clinical trials in premenopausal women with hypoactive sexual desire disorder showed improvements in desire and reductions in distress, which led to approval in 2019. The most common adverse effects were nausea, flushing and headache, and transient increases in blood pressure were observed. Because it acts centrally, it does not interact with nitrates in the way PDE5 inhibitors do, which is a meaningful pharmacological difference. The effect is not instantaneous, and trials generally measured desire over hours rather than immediate arousal, which shaped how the drug was positioned.

Strength, Pack and Authentication

Each vial contains 10 mg of lyophilised bremelanotide, sealed and packed in a printed carton stating the compound, strength and vial count. A scratch-off security code inside the box can be verified against Hilma Biocare's records. The powder is stable before reconstitution and intended for research use only.

Buying PT-141 Online

PT-141 is one of the most searched sexual-health peptides. If you are researching bremelanotide, comparing PT-141 products or looking to buy PT-141 online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare sexual-health products at NotNatty.